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Halogenases: a palette of emerging opportunities
for synthetic biology–synthetic chemistry and
C–H functionalisation
Charlotte Crowe,†‡ Samuel Molyneux,‡ Sunil V. Sharma, Ying Zhang,
Danai S. Gkotsi,§ Helen Connaris and Rebecca J. M. Goss *
The enzymatic generation of carbon–halogen bonds is a powerful strategy used by both nature and
synthetic chemists to tune the bioactivity, bioavailability and reactivity of compounds, opening up the
opportunity for selective C–H functionalisation. Genes encoding halogenase enzymes have recently
been shown to transcend all kingdoms of life. These enzymes install halogen atoms into aromatic and
less activated aliphatic substrates, achieving selectivities that are often challenging to accomplish using
synthetic methodologies. Significant advances in both halogenase discovery and engineering have
provided a toolbox of enzymes, enabling the ready use of these catalysts in biotransformations, synthetic
biology, and in combination with chemical catalysis to enable late stage C–H functionalisation. With a
focus on substrate scope, this review outlines the mechanisms employed by the major classes of
halogenases, while in parallel, it highlights key advances in the utilisation of the combination of enzymatic
halogenation and chemical catalysis for C–H activation and diversification.
Introduction
Halogenated organic compounds play an important role in
society. In the agrochemical sector, a staggering 96% of herbi-
cides, fungicides, insecticides, acaricides and nematicides pro-
duced since 2010 contain halogen atoms.1 Such compounds are
valuable commodities; for example, the top-selling insecticide
imidacloprid (Fig. 1A) 1 had sales of 1.09 billion USD in 2011
alone,2 and in 2013, 50% of marketed top drugs contain
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halogen atoms.3,4 The fluorinated hepatitis C ledipasvir/
sofosbuvir combination (Harvonis) 6 was the second best-
selling blockbuster pharmaceutical in 2016 with USA sales
revenues of 4.9 billion USD (Fig. 1B),5 whilst, in the same
year, US sales of the chlorinated antihistamine loratadine
(Claritins) 11 exceeded 2 billion USD.6 An economic report
analysing the annual sales of the 100 top selling pharmaceu-
ticals reveals that 12.9% of the final active pharmaceutical
ingredient (API) is chlorinated or brominated, whilst a
further 62.7% require chlorination at some stage in their
manufacture.7
The incorporation of a carbon–halogen bond is a regularly
employed strategy in medicinal and agro-chemistry. Due to
bond polarisation and the ability to form highly directional
halogen bonds to electron-rich oxygen, nitrogen, sulfur and
aromatic rings, halogen incorporation may be used to enhance
stability, and increase lipophilicity which in turn can influence
bioavailability and modulate compound bioactivity.8 Beyond these
applications, series of fluorinated and iodinated compounds are
used in radiotherapy and biomedical imaging.9,10 Halogenation is
also central to molecule construction and manufacture. The
reactivity and chemical orthogonality of organohalides enables
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many selective transformations including, most notably, cross-
coupling and substitution chemistries. Synthetically, the
generation of organohalides is currently achieved through the
addition of molecular halogens, hydrohalogenation, or the use of
reagents enabling nucleophilic substitution and electrophilic
aromatic substitution [EAS]. These reactions are generally
accompanied by environmental and selectivity challenges due to
the toxic, corrosive and reactive nature of the reagents used, and
the propensity to generate complex product mixtures.11 Whilst
recent advances in homogenous catalyst design has meant more
selective catalytic approaches towards halogenation are known,
such catalysts can be complex, costly and time consuming to
synthesise.12
Though naturally occurring organohalides were initially
speculated to be nothing more than a biological curiosity,
artefact, or to be anthropogenic in origin, today, over 5000
halogenated natural products are known, with genes encoding
halogenases identified across all kingdoms of life.13 These
represent a resource for greener and often highly regioselective
halogenation. An increased appreciation of mechanisms
underpinning enzymatic halogenation has evolved over the
past 25 years, and may broadly be classified as electrophilic,
nucleophilic or radical halogenation. Whilst a good level of
understanding of the enzymatic active sites and structural
requirements of these enzymes exists, a number of fundamental
details remain to be elucidated.
Fig. 1 Examples of commercially important and structurally diverse organohalides. (A) Examples of top-selling halogenated agrochemicals include
imidacloprid 1, biggest selling insecticide 2011 sales of 1.09 billion USD per annum;2 acetochlor 2, herbicide in the top 10 best-selling agrochemicals in
2003;16 epoxiconazole 3, a triazole based fungicide with sales of 215 million USD in 2001;17 and fipronil 4, a pyrazole based insecticide with sales of
270 million USD in 2001.17 (B) Examples of top-selling halogenated pharmaceuticals include antidepressants fluoxetine 5 (Prozacs)17 and citalopram 7
(Celexas);18 anti-hepatitis C agent ledipasvir 6;5 statin rosuvastatin 8;19 the blood thinner clopidogrel 9;16 the type 2 diabetes treatment sitagliptin 10;20
and antihistamine loratadine 11.6
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This review overviews the mechanisms of the different
classes of halogenases, the natural context of the halogenases,
their biocatalytic applications, and explores their powerful
potential for use in the hyphenation of Synthetic Biology
and Synthetic Chemistry (SynBio–SynChem) enabling C–H
activation and diversification.
1. Mechanisms for biocatalytic halogenation
Enzymatic halogenation is classified mechanistically in accordance
with whether the halogen is introduced by an electrophilic, nucleo-
philic, or radical halide species, with the vast majority of the
enzymes that have been discovered so far, being electrophilic
halogenases, mediating oxidation of the halogen to generate a
reactive electrophilic species. There is further subdivision within
the broader halogenase categories, based on the exact catalytic
species and cofactor which enables halogen oxidation.
1.1 Electrophilic (X+) halogenation
1.1.1 Haloperoxidases. Haloperoxidases are defined as
enzymes that utilise hydrogen peroxide and chloride, bromide
or iodide to generate HOX. These enzymes are named in
accordance with the most electronegative halogen for which
they can affect oxidation. Haloperoxidases are generally the
least regioselective of the enzymes enabling halogenation;
catalysing the generation of free hypohalous acid, which in
all but a few cases, is released by the enzyme. The earliest
reported studies of halogenation enabled by an enzyme date
back to 1959, when Lowell Hager discovered a haloperoxidase
(HPO) from the fungus Calariomyces fumago.14 The enzyme that
Hager had utilised as part of a lysate was named chloroperoxidase
or (CPO) and was shown to be capable of affecting dichlorination
of 1,3-cyclopentanedione 12. It has thus been postulated to be
involved in the biosynthesis of the antibiotic caldariomycin 14
(Scheme 1C).15 CPO may be described more specifically as a
heme iron-dependent haloperoxidase, a subset of haloperox-
idases that contain a heme-iron cofactor coordinated to an axial
cysteine ligand within the enzyme. Hydrogen peroxide binds
axially to heme-Fe(III) in its resting state to form a +heme-
Fe(IV)QO intermediate, denoted compound I.23 Addition of
halide to the ferryl oxygen produces a heme-Fe(III)–OX species
(Scheme 1A, IV). Free hypohalous acid, HOX, is generated
which reacts with an electron-rich substrate (Scheme 1A).24
Generation of electrophilic X+ allows halogenation of electron-
rich compounds by electrophilic aromatic substitution,
generally at the most reactive site(s) within the substrate.
CPO has been used biocatalytically to mediate the chlorination,
bromination or iodination of a variety of electron-rich
substrates (see Section 2), however, as it lacks a site to position
the substrate, no regiocontrol beyond that conferred by the
electronics of the substrate is observed.
The vanadium-dependent haloperoxidases (V-HPOs) operate
by an analogous mechanism, again generating and, mostly
releasing, free hypohalous acid. This subcategory of haloperox-
idase is widely found in algae, fungi and bacteria, and utilises a
vanadium cofactor bound by an axial histidine ligand.25 In the
resting state, the cofactor is in a trigonal bipyramidal configu-
ration (Scheme 1B, V), a distal H2O2 displaces two hydroxyl
ligands giving rise to formation of the known Z2-peroxido
complex (Scheme 1B, VII), with the distorted square pyramidal
geometry. Though the exact order of events and level of protona-
tion here is not known, a postulated catalytic cycle is shown. A
lysine residue hydrogen bonded to an equatorial V–O oxygen
activates the peroxide complex for X attack and a return to the
Scheme 1 Haloperoxidase HOX generation and utilisation. (A and B) Biocatalytic cycle of heme iron-dependent and vanadium-dependent haloper-
oxidases, respectively, showing the release of freely diffusible hypohalous acid (NB the order of events in B remains unclear, with the protonation state of
VII being ambiguous).21 (C) Chlorination of 1,3-cyclopentanedione 12 by HOCl in the presence of a heme iron-dependent chloroperoxidase (CPO) and
hydrogen peroxide suggested to occur in caldariomycin 14 biosynthesis.15 (D) The reaction of monochlorodimedone (MCD) 15 with HOX, the
benchmark assay for haloperoxidase activity.22
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trigonal bipyramidal geometry (Scheme 1B, VIII) is observed.
The resulting V–OX species undergoes hydrolysis to generate
electrophilic X+ in the form of free HOX.26 Electrophilic aromatic
substitution occurs, as in the case with heme-iron
haloperoxidases.27 A notable difference with the heme iron-
dependent biocatalytic cycle is that the vanadium centre main-
tains its oxidation state throughout the process.28
Haloperoxidases had initially been considered to lack
significant enzyme-mediated selectivity due to the release of
freely diffusible hypohalous acid. The free electrophilic species
allows halogenation at the most electron-rich carbon, and a
mixture of mono-, di- and tri-substituted products can often be
observed. Detection of the free HOX through reaction with
nucleophilic monochlorodimedone (MCD) 15 has previously
been used to assay for haloperoxidase activity (Scheme 1D).29
However, for a number of vanadium-dependent haloperoxidases,
substrate, regio- and even stereo-specific halogenation is evident,
as noted in the biosynthesis of napyradiomycins 76,30 and
merochlorins 77, 78.31 (Scheme 5). Currently, the exact
mechanistic rationale for this specificity is not known. Here,
free HOCl is notably not detected in assay with MCD.31 It is thus
postulated that residues within the enzyme might transiently
support the electrophilic HOCl, whilst the electron-rich substrate
is appropriately and proximally positioned. Moore invokes the
involvement of an active site lysine forming a haloamine, in a
manner analogous to the FDHs.31,32 Though NapH1 from napyr-
adiomycin biosynthesis is associated with the first chlorination
event, this enzyme is also capable of mediating nonspecific
bromination through generation and release of HOBr.
Greater understanding of the mechanism enabling selective
halogenation by these series of enzymes would be valuable,
potentially enabling informed discovery of further enzymes with
biotechnological potential.
1.1.2 Flavin-dependent halogenases. The haloperoxidases
remained the only known halogenases for several decades until
in 1995, the first of a second series of halogenases, the flavin-
dependent halogenases (FDHs), Chl from 7-chlortetracycline 73
biosynthesis in Streptomyces aureofaciens was revealed in a
study by Dairi.33 The enzyme was implicated as being involved
in chlorination with knockouts of the gene encoding Chl
lacking halogenated product. However, from these initial stu-
dies, it was not fully apparent that this new series of enzymes
were flavin-dependent, only a partial protein sequence lacking
100 amino acids at the N-terminal end including the flavin
binding site. In vitro analysis of the tryptophan 7-halogenase
PrnA, by van Pée and co-workers, demonstrated the powerful
regioselectivity of this new class of halogenase and the requirement
for both flavin and molecular di-oxygen.34,35
The FDHs can be separated into those acting on free
substrates (variant A), and those requiring their substrate to
be covalently tethered to a carrier protein via a phosphopan-
tatheine linker (variant B).36 The most extensively investigated
and engineered FDHs are the tryptophan halogenases, variant
A FDHs enabling regioselective halogenation of tryptophan at
the 5, 6 or 7 positions. The first structural insights as to how
FDHs mediate their exquisite regioselectivity were revealed by
van Pée and Naismith.37 However, 15 years on and debate still
remains as to the exact way in which these enzymes function.
Details as to which residues within the active site participate
may vary from one enzyme to another. The mechanisms
proposed by Walsh38 and van Pée39 for the flavin dependent
tryptophan halogenase are presented in Scheme 2B and C.
Reduced flavin adenine dinucleotide (FADH2), (Scheme 2A,
I) and dioxygen in the presence of chloride, bromide or iodide
are utilised by these enzymes to catalyse C–H to C–X. Freely
diffusible FAD binds to a conserved GxGxxG motif. The reduced
cofactor, FADH2, (Scheme 2A, II) reacts with molecular oxygen
to form FAD(C4a)–OOH (III), which subsequently reacts with a
nucleophilic halide releasing HOX and FAD(C4a)–OH
(Scheme 2A, IV).40 Unlike haloperoxidases, the HOX generation
and electrophilic aromatic substitution (EAS) events are spatially
separated by a B10 Å tunnel. At the end of this tunnel is a
conserved lysine, proposed by Walsh to react with the HOX
thereby forming a haloamine intermediate, guiding the regio-
chemistry of halogenation. (Scheme 2B).38 Mutation of this
lysine residue to alanine, across a series of halogenases
including RebH, PrnA, and Rdc2, results in loss of activity.41 In
a subtly different mechanism, van Pée invokes a proximal
glutamate residue, as well as the lysine residue binding to
HOX, thereby activating it and positioning it (Scheme 2C).39 In
both models, the electrophilic halogenating species is directed
towards the substrate, promoting a regioselective EAS reaction.
The exact mechanism and halogenating species remain elusive.
Mutation of this active site glutamate to glutamine in PrnA
results in a drop in rate by two orders of magnitude.37 This
glutamate is not present in the more electron-rich phenol
halogenases. A different proposed role for this active site glutamate,
invoked in deprotonation of the Wheland intermediate indole
benzo ring in the tryptophan halogenases, is that it perhaps plays
a role in reducing the activation energy of halogenation of these
less electron-rich species.41 Notably no kinetic isotope effect is
observed for halogenation of tryptophan by RebH.42
These FDHs share a similar flavin binding domain to the
flavin-dependent monoxygenases, and though most utilise free
and diffusible FAD, which is converted to FADH2, variants exist
where the flavin is covalently bound to the enzyme, such as in
the case of CmlS involved in chloramphenicol biosynthesis.44
Naturally, most FDHs are usually provided the reduced flavin
by a partner flavin reductase that utilises NADH (nicotinamide
adenine dinucleotide) and FAD to generate reduced FADH2.
35
The partner flavin reductase can be readily substituted for any
other capable of producing FADH2. Single component FDHs,
that have this reductase function present within the one
protein, also exist; the first discovered example of such an
enzyme was Bmp5.45 This enzyme shows other notable differences
to all previously studied FDHs; in analogy to the decarboxylative
hydroxylation observed for a single component monooxygenase,
decarboxylative dibromination of 18 occurs (Fig. 2F).45 Other
intriguing variations of the FDHs also exist, recently, the first of a
new class of zinc-binding FDHs, MalA from the biosynthesis of
the malbrancheamides 21 and 22 (Fig. 2G) was reported.
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This remarkable enzyme is capable of mediating the late stage
dichlorination of 5, and 6 positions of the indole benzo ring of pre-
malbrancheamide 20, a complex prenylated indole alkaloid. In the
first step, positions 5 and 6 appear to be halogenated with
comparable rates, perhaps due to increased electron density, the
second halogenation even occurs far more quickly. Within the
enzyme, the active site glutamate is seen proximal to the NH of
the indole. It is clearly implicated in deprotonating this moiety,
rendering the substrate more nucleophilic, and whilst mutation of
this glutamate to aspartate results in low but observable activity,
mutation to glutamine renders the enzyme inactive.46
FDHs contain multiple sequence motifs; a series of amino
acid residues integral for enzyme activity or structure, that are
generally conserved throughout all FDHs. These are a
dinucleotide-binding motif GxGxxG, part of the Rossman fold
allowing for binding of flavin and NAD(P)H,49 and a tryptophan
motif WxWxIP, suggested to block binding of substrate near the
bound cofactor, thus preventing a monooxygenation reaction
instead of halogenation.37 It is notable though, that GxGxxG,
the flavin binding motif is present in almost all flavoenzymes.
The WxWxIP motif or variants of this motif, is known to be
absent in a number of FDHs including the more unusual
Bmp5.48 A new motif, Fx.Px.Sx.G was recently reported. This,
or variants of this motif in which G is replaced with a charge
bearing residue, line the tunnel between the flavin binding site
and the site of halogenation, may be found in all active FDHs.47
As such, it can be used as a method for quickly identifying
candidate FDHs from uncurated sequence data. A complementary
and overlapping motif FX[DE]PX[EFL] was subsequently identified
by Lewis and coworkers.157
Notably, almost all halogenases studied, until recently, have
been identified from bacteria and fungi, most being found due
to their implication in the biosynthesis of a specific natural
product or series of natural products. Iodination had also been
missing from the FDH portfolio of reactions, though postulated
to be involved in the biosynthesis of iodinated natural
products.50 Whilst efforts had been made to explore the utilisation
of enzymes such as RebH for iodination, incubation of such
Scheme 2 FDH-mediated electrophilic halogenation. (A) Biocatalytic cycle of a flavin-dependent halogenase, showing the release of hypohalous acid.
HOX is channelled through a B10 Å tunnel. The regioselectivity of the electrophilic aromatic substitution is postulated to be achieved by: (B) a lysine
residue, at the end of the tunnel that reacts with HOX to form a haloamine intermediate,43 and (C) lysine and glutamine, acting in concert to position HOX
and further electronically activate the tryptophan.39 (D) Extrapolation of the crystal structure of PrnA showing how Lys79 is positioned over C7 of the
indole ring mediating regioselective halogenation.
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enzymes with iodide had been unfruitful, and competition studies
had revealed that the presence of such salts procluded conversion,
perhaps due to formation and inability to release the bulky
product.43 More recently the FDH, PltM, was shown to be able
to process sodium iodide, though preference for bromination,
then chlorination was apparent.51 VirX1, the first halogenase to be
characterised from a virus, is the first FDH for a preference for
halogenation, and may be seen to have a large and readily
accessible active site (Fig. 2A and B). Hydrophobic residues anchor
the substrate in position, enabling regiospecific halogenation as
guided by the proximal lysine (K79). Glutamate enables further
activation, of otherwise less electrophilic substrates. It is
postulated that by virtue of openness of this active site not only
can a large range of small to sterically bulky substrates be
processed, but halogenation by the largest and most readily
oxidised of the halides is enabled.47
1.2 Radical (X) halogenation. The halogenation of less
electron-rich alkyl groups requires a different enzymatic strat-
egy compared to the halogenation of activated aryl moieties.52
To achieve these energetically less favourable halogenations,
radical chemistry is employed. Just as electrophilic FDH utilises
similar enzymatic machinery to flavin dependent monooxygenases,
Fig. 2 Unusual FDHs. (A) Trimer of VirX1, the first FDH with a preference for iodination, and the first halogenase from a virus showing the large and
accessible active site, with a bulky substrate 16 modelled in the active site. (B) View of a subunit of VirX1, again with substrate 16 modelled into the active
site, and embedded in a hydrophobic cleft. (C) Key hydrogen bonds between VirX1 and 16 as predicted by structural modelling. (D) Regiospecific
iodination of 16 by VirX1.47 (E) Model of compound 16 in the active site of VirX1. (F) Decarboxylative bromination of 18 observed for Bmp5.48 (G) Iterative
dihalogenation in malbrancheamides 21 and 22 biosynthesis, by an unusual zinc-containing FDH.46
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analogously, non-heme iron a-ketoglutarate (KG)-dependent
(NHFe) halogenases (NHFeHals) may well have evolved from
their hydroxylase counterparts. Understanding of the catalytic
cycle mediated by the NHFeHals is informed by the studies of
the hydroxylases, which also require a non-heme iron centre,
a-KG and O2 to function (Scheme 3). The catalytic cycle may
notionally be considered to start with octahedral FeII coordinated
in a bidentate fashion by a-KG, and a weakly bound water ligand
that is subsequently replaced by molecular oxygen. The remaining
three positions, a ‘‘facial triad,’’ in hydroxylases, consists of two
histidine residues and the carboxylate of either an aspartate or
glutamate residue at the active site.53 In halogenases, this
carboxylate residue is usually found to be replaced by either an
alanine or glycine, thereby enabling the halogen ion to coordinate
at this vacant coordination site (Scheme 3, I). It has been shown
that the weakly bound axial water ligand is initially displaced by
substrate binding, triggering the subsequent reaction of II with
molecular oxygen.54 Oxidative decarboxylation of III affords
trigonal bipyramidal IV, with succinate coordinated, and is the
driving force for the catalysis. This high valent, high energy FeIV-
oxido species is capable of abstracting H from an otherwise
unactivated alkyl group.55 The regio-selectivity of abstraction is
governed by how the substrate is positioned within the enzyme’s
active site. Selectivity for reaction of generated substrate radical
with Fe(III)–X bond, leading to the desired halogenation over the
Fe(III)–OH bond, which would lead to hydroxylation, is thought to
be controlled by careful substrate positioning over FeIII species
V.56 In HctB, a NHFeHal from hectochlorin biosynthesis, residues
such as the Glu223 and Arg254 are thought to influence the
charge density of the chlorine ligand, and are thus postulated
to further promote halogenation.57 The resultant alkyl radical
proceeds to extract X from V, returning the metal centre to its
FeII state.
Significant conformational changes are observed within these
NHFe proteins. These changes are postulated to occur directly
after oxygen binding and the subsequent decarboxylation event,
orientating the substrate for the observed regioselective halo-
genation. Crystal structures of WelO5 with NO (an O2 analogue)
reveal a significant change in conformation. Initially, NHFeHals
appeared to be difficult to handle in vitro due to oxygen
sensitivity of the Fe(II) core,58 however, recent advances suggest
an iron-reconstitution step can be performed to activate enzymes
purified aerobically.59 The majority of NHFeHals, such as
SyrB1,58 BarB1 and BarB2,60 and CurA halogenase,61 like the
variant B FDHs, all required the substrate to be presented on
carrier proteins, tethered via a phosphopantatheine linker
(Ppant). In 2014, WelO5 was discovered, becoming the first
member of a new family of NHFeHals (that we will refer to as
variant A NHFeHals), which act on freestanding substrates.62
Excitingly, these open up the possibility for using such proteins
more readily in biotransformations.
1.3 Nucleophilic (X) halogenation. Though the C–F bonds
are prevalent in pharmaceuticals, and fluorine is the most
abundant of the halogens on earth, few fluoro-metabolites are
known. So far, 13 fluorometabolites, 7 of these being closely
related fluorinated lipids, have been discovered. The bacterium
Streptomyces cattleya is known to biosynthesise three of this
limited portfolio of fluorinated metabolites: fluoroacetate,
4-fluorothreonine, and (2R,3S,4S)-trihydroxy-5-fluoropentanoic
acid. These compounds are generated by the ‘‘fluorinase,’’
more formally named adenosyl fluoride synthase or FlA, that
was discovered by O’Hagan and co-workers.63 FlA is closely
related to the more recently discovered SalL, an enzyme that
mediates chlorination in salinosporamide biosynthesis.64
These enzymes are members of a rare group of nucleophilic
halogenases, all of which utilise S-adenosyl-L-methionine 23
(SAM) as substrate. Streptomyces calvus is capable of biosynthe-
sising a fourth bacterial fluorometabolite, nucleocidin.65
Intriguingly, a gene with similarity to that which encodes the
fluorinase is absent from the genome of this organism
implying that a further group of halogenases capable of
mediating C–F bond formation exists. The dearth of fluoro-
metabolites found in nature may perhaps be attributed to a
number of factors. With the high electronegativity of fluorine,
the possibility of oxidation to generate a fluorous electrophile
or even a fluorous radical is energetically challenging, and no
enzymes have so far shown this capability. Also, fluoride,
though abundant, is generally present in minerals such as
fluorospar (fluorite), which have high lattice energies and poor
solubilities. Once in solution, fluoride is surrounded by a
sheath of water, its high enthalpy of hydration (490 kJ mol1)
precludes ready displacement of the water molecules to access
the naked fluoride ion required for nucleophilic attack.66
The nucleophilic halogenases characterised so far all operate
by holding the halide proximal to the electrophile, SAM. Crystal-
lographic studies of the fluorinase reveal a small pocket, the
fluoride binding site, giving insight into how displacement of
the hydration sphere might be achieved. Whilst predominantly
hydrophobic, this small pocket contains a serine.67 Dehydration
is proposed to occur when SAM binds with the positive charge on
the sulphur possibly assisting with stabilisation of the naked
fluoride. The requirement for the fluoride ion to bind first in
order for a productive complex to be formed, is argued based on
observed substrate inhibition by SAM. Within the crystal
structure, SAM may be seen bound with its ribose ring forced
Scheme 3 Radical halogenation. Biocatalytic cycle of a non-heme iron
a-ketoglutarate-dependent halogenase, showing the release of haloge-
nated product.
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into a high energy, eclipsed conformation. The halide anion is
positioned collinearly with the SAM C–S bond, thus promoting
an SN2 backside attack (Scheme 4).
67 When the enzyme is
crystallised in the presence of both SAM and fluoride, the
products L-methionine and 50-fluoro-50-deoxyadenosine (50-FDA)
with the ribose ring in the relaxed conformation may be observed.
The fluorinase has a strong preference for fluoride, but can
incorporate chloride to a low level.68 SalL, from Salinispora
tropica bacterium has 54% sequence similarity to the fluorinase,
and in the halide binding pocket, a glycine residue resides in
place of a serine. This enzyme shows a strong preference for
chlorination and, whilst capable of utilising bromide and iodide,
it cannot process fluoride.64
Notable uses of the fluorinase include exploration of its
application to 18F incorporation for positron emission tomo-
graphy (PET),69 and it’s the utilisation of the fluorinase in
parallel with a polyketide synthase to enable synthetic biological
access to simple fluorinated polyketides.70
1.4 Biocatalytic potential. The halogenases offer great
potential for use as biocatalysts. To realise the application of
these important enzymes, the regio-control, -selectivity and
reaction rate afforded by the different classes of enzymes is
important to consider. The reported exploration of kinetics for
the halogenases in the literature is both sparse and varied, and
can be challenging to compare due to the different ways in
which the data are obtained. We compile a representative
overview of the kinetic analyses available for different families
of halogenases for a brief comparison between families
(Table 1), as well as a glossary of the halogenases that have been
structurally characterised so far (Table 2). Haloperoxidases,
such as CPO, may be seen to have high turn-over numbers
(Kcat 33  1 min1), yet such catalysts that may be utilised to
halogenate a broad series of substrates (see Section 2) lack regio-
control. Conversely, the NHFeHals also have a high turn-over
number, mediate a highly regio-selective reaction, but the nat-
ural reaction that its catalyses is much slower than CPO (Kcat/Km
0.0525 vs. 1.22 mM1 min1, Table 1).
2. Natural and unnatural aromatic substrate scope for
biocatalytic halogenation
2.1 Indolic substrates
2.1.1 Early stage halogenation in biosynthetic pathways.
Indoles are commonly utilised motifs in medicine and agro-
chemistry, and new tools that enable their chemical diversifica-
tion are desirable. There are a series of FDHs that allow for this
diversification, via halogenation. Many FDHs mediating the
regiospecific halogenation of the indole moiety of tryptophan
have been found so far. Most of these enzymes have been found
to be involved in the early stages of bioactive natural product
synthesis. Such enzymes include PrnA and RebH, tryptophan 7-
halogenases, from the first step of the biosynthesis of the
antibiotic pyrrolnitrin 24 and the indolocarbazole anticancer
agent rebeccamycin 36, respectively.35,43 Tryptophan 6-
halogenases include ThdH (alternatively known as ThaI) from
the first step of thienodolin 25 biosynthesis, a plant growth
promoting compound,71 SttH identified in silico adjacent to an
NRPS cluster,72 SatH from Streptomyces albus,73 BorH, a ther-
mophilic halogenase from borregomycin 33–35 biosynthesis,74
and AfnX responsible for generating the 6-chlorotryptophan
precursor of alboflavusin A 26. Alboflavusin is an analogue of
the dimeric non-ribosomal peptide (NRP) anti-tumor agent and
apoptosis inducing agents, himastatin and chloptosin.75
Though less common so far, 5-chlorotryptophans may also
be seen as motifs in natural products. Examples include the
antibiotic pyrroindomycin B 27; the first step in the biosynth-
esis of this compound is the generation of 5-chlorotryptophan
by PyrH.76 Sequence analysis of Xenorhabdus szentirmaii
revealed a further flavin dependent tryptophan 5-halogenase
XszenFHal. Though the natural function of this halogenase
remains unknown, it was demonstrated to be capable of
Scheme 4 Nucleophilic halogenation. Halogenation of S-adenosyl-L-
methionine 23 (SAM) by X mediated by a nucleophilic halogenase,
yielding L-methionine and 50-halo-5 0-deoxyadenosine.67
Table 1 Representative electrophilic (VirX1, PltM, PyrH, CPO, V-BrHPO), nucleophilic (FlA) and radical halogenases (WelO5, PfHalA) and their kinetic
parameters with respect to substrate at set concentrations of other cofactors. ND = no data published
Enzyme Substrate Classification Halide kcat (min
1) KM (mM) kcat/KM (mM
1 min1) Ref.
VirX1 6-Azaindole FDH I 5  0.5 28  2 0.179  0.004 47
Br 2.4  0.6 53  3 0.044  0.008
PltM Resorcinol FDH Br 1.9  0.1 0.71  0.3 2.7  0.6 51
Cl 2.3  0.1 0.076  0.013 30  5
PyrH Tryptophan FDH Cl 3.56  1.1 109  44 0.0325  0.017 51
KtzQ 7-Cl-L-Tryptophan FDH Cl 1.4 114 0.012 82
MalA Premalbrancheamide FDH Cl 0.08  0.05 7.0  2.9 11.49  0.02 46
WelO5 12-Epi-fisherindole U NHFeHal Cl 1.8  0.2 ND ND 83
PfHalA Lysine NHFeHal Cl 14.7  0.71 280  60 0.0525  0.0118 84
AdeV 20-Deoxyadenosine monophosphate NHFeHal Cl 0.6 2500 0.24  103 85
CPO Catechol HPO Cl 33  1 27  8 1.22  0.36 86
V-BrHPO 2-Chlorodimedone V-HPO Br 5 ND ND 26
FlA SAM Nucleophilic F 0.07  0.001 6.5  0.3 0.0108  0.0005 87
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regioselectively halogenating a series of indolic and anthranilic
substrates.77
The first successful demonstration of the ability to modify
the regioselectivity of a FDH was via site directed mutagenesis
of tryptophan 7-halogenase PrnA. The modification of a large
phenylalanine residue in the active site to a smaller alanine
allowed for a different binding orientation of tryptophan,
leading to halogenation at the 5 position, though it must be
noted that halogenation at the 7 position still dominated (2 : 1
ratio of 7-/5-bromination).78 Despite useful changes in selectivity
being rare, there are a number of further successes.42,79 Positioning
of the lysine residue over the substrate was thought to be critical
to site of halogenation. Various studies toward gaining deeper
understanding of subtle factors beyond the positioning of the
lysine residue in the active site have been carried out, including
structural comparison of PyrH, SttH and PrnA, and, specifically, a
loop proximal to the active site, informing the design of mutants
with modified regiochemistries.80 Modifications to ThaI, to
promote chlorination at the 7 position, rather than the 6 position
have also been reported.81
Biosynthesis of 4-chlorotryptophan remains a mystery.
Although it was isolated from immature pea seedlings in 1970,
and postulated to be a precursor to a plant growth hormone,115
the halogenase has not yet been found, hinting that it may be
strikingly different to the other, well known FDHs. There have
also been fewer reports of natural products containing 2-
halotryptophans, perhaps due to their inherent instability. The
keramamides 30116 and linked family of jaspamides, chondra-
mides 28 are two exceptions, with CmdE implicated in the
generation of 2-chlorotryptophan,117 though for this enzyme,
no activity with free tryptophan can be shown. It is not clear as to
whether lack of observation of production of this species by
CmdE is due to the enzyme requiring a different substrate or due
to the instability of the product. 2-Chlorotryptophans are very
unstable and both the free amine and carboxy groups might be
considered to promote dechlorination.
Tryptophan halogenases capable of halogenating substi-
tuted tryptophans are also known. These include the trypto-
phan 6-halogenase KtzR, which acts in tandem with KtzQ in the
first steps of kutzneride 29 assembly, installing a second
chlorine into the 7-chlorotryptophan that KtzQ generates118
and KrmI, another tryptophan-6-halogenase, which processes
4-hydroxy-tryptophan as its natural substrate, though the wild
type enzyme shows ability to process a fairly broad range of
Fig. 3 Halogenated natural products arising from the halogenation of indolic substrates: all include regioselective halogenation of tryptophan as a first
step in their biosynthesis (tryptophan halogenase name and regiochemistry noted below each corresponding natural product). Examples include (C7)
pyrrolnitrin 24,120 (C6) thienodolin 25,71 Di-alboflavusin A1 26,75 (C5) pyrroindomycin B 27,76 (C2) chondramide D 28117 (C6, C7) kutzneride 29,121
keramamide A 30116 Tryptophan halogenases involved in the biosyntheses of these natural products are depicted, and are colour coded in accordance
with the regiochemistry of the halogenation that they mediate. Chlorination is indicated in blue. Different regio-chemistries for chlorination are
represented by different shades of blue.
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other substrates. KrmI is an unusual halogenase, involved in
the biosynthesis of the keramamides 30, this FDH is transla-
tionally fused to a ThiF protein119 (Fig. 3).
A large variety of symmetrically and asymmetrically halogenated
indolocarbazole compounds are known, including the cladonia-
mides 31, 32,122 borregomycins 33–35,123 and rebeccamycins 36,
37.40 From genomic analysis of the producing organisms, the first
step in the biosynthesis of these compounds also involved the
generation of 5, 6 or 7-halotryptophan. This biosynthetic logic has
been utilised to enable the generation of combinatorial libraries
of known and novel compounds in which halogenation and
glycosylation patterns are modulated.124 Similar to these
compounds are the bisindole alkaloids indimicins and related
spiroindimicins 38–40 (Fig. 4).125
The tryptophan halogenases have been previously thought
to possess only modest innate substrate flexibility. RebH is
capable of processing tryptolines, whilst KrmI will halogenate
unsubstituted indoles and fluoro-tryptophan.42,119 The tryptophan
halogenases continue to be subject to extensive rational reengineering
and directed evolution due to their potential as tools for biocatalysis.
In addition to studies that explore and modulate factors
governing regiocontrol, considerable effort continues to be
invested in extending substrate scope.41 Wild-type RebH (the
tryptophan 7-halogenase from rebeccamycin 36 biosynthesis)
has been demonstrated to be capable of regioselectively halogen-
ating a series of indolic (Fig. 5) and arene substrates (Fig. 9).126
Natural substrate scope for the FDHs RebH, GsfI, ThaI and
Rdc2 is seen to be a little broader, and these enzymes have
capability to process a range of indolic substrates.42 Directed
evolution of RebH has been employed by the Lewis group to
tune the enzyme for use in 7- 44, 6- and 5-chlototryptamine
generation enabling quantitative conversions in some
instances, and high selectivities.42 Evolved RebH variants have
been employed, achieving selective late stage functionalisation
of chlorination of sterically bulky substrates, including tricyclic
tryptolines 50–53 and large indole carbazoles 56, 57, improving
conversions of these unnatural substrates as well considerably
extending substrate scope from what was previously known
(Fig. 4).126,127
Production of halogenated indolic substrates by flavin-
dependent halogenases is commonly reported at small
scale.47,126,127 The use of Cross-Linked Enzyme Aggregates
(CLEAs), in which the physical aggregation of enzymes with a
cross-linking agent is mediated, can enable enzyme stabilisation
and enhanced yields. By crosslinking RebH and PrnF (the PrnA-
related reductase) with glutaraldehyde, Sewald was able to achieve
yields on a gram scale with CLEAs for the halogenation of L-tryp-
tophan, D-tryptophan and L-5-hydroxytryptophan, establishing the
foundations for halogenase biocatalysis on a preparative scale130
(see Section 3).
2.2 Phenolic substrates. Phenolic quinolines attract attention
for their many and varied medicinal properties such as antima-
larial, antibacterial and anticancer activities.131 Structure–activity
relationship (SAR) reveal that installation of a chlorine or bromine
atom within the quinoline ring of antitubercular quinolines can
enhance their activity.131 Beyond antitubercular uses, chlorine-
Fig. 4 Naturally occurring halogenated bisindole alkaloids. These compounds incorporate a halogen into tryptophan in the first stage of their
biosynthesis. (The tryptophan halogenase responsible and its regioselectivity that it confers, are noted below each natural product.) Examples include
indolocarbazoles (C5) cladoniamide A 31,122 (C5) BE-54017 32,128 (C6) borregomycins B 33, C 34 and D 35123 (C7) rebeccamycin 36,40 (C7) AT2433-A1
37,129 (C5) spiroindimicins 38–40.125 Non-halogenated analogues of the latter have been accessed through deactivation of SpmH.125 Tryptophan
halogenases involved in the biosyntheses of these natural products are depicted, and are colour coded in accordance with the regiochemistry of the
halogenation that they mediate. Chlorination is indicated in blue. Different regio-chemistries for chlorination are represented by different shades of blue.
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containing 8-hydroxyquinoline derivatives are being explored for
treatment of Alzheimer’s disease.132 Phenols, being electron-rich,
are frequently seen to be good substrates for electrophilic
enzymatic halogenation (Fig. 8 and Scheme 5). While the haloper-
oxidases generally confer limited specificity, the FDHs show good
levels of regiocontrol for accessing such halogenated compounds.
2.2.1 Early stage halogenation by FDH variant B enzymes.
Whilst there has been considerable and detailed investigations
of a number of the variant A halogenases that work on
substrates that are not covalently tethered to a carrier enzyme
(in particular the tryptophan halogenases), fewer in vitro
investigations of variant B halogenases have been published.
However, a diverse range of bioactive natural products that
contain halogenated phenols have been isolated. Here, the
operation of variant B FDHs may be seen to be prevalent, and
investigations indeed indicate many of the substrates to be
enzyme tethered. Halophenol-containing natural products
include the actinobacteria-produced aminocoumarins clorobiocin
58 and simocyclinone D8 59. The initial steps of the biosyntheses
of these metabolites are postulated to include halogenation of
enzyme-tethered tyrosine (mediated by Clo-hal and SimX1,
Fig. 5 Representation of some of the diverse substrate scope of tryptophan halogenases. Enzymes include (A) wild-type RebH chlorinating indoles;42,126
(B) evolved RebH 3-SS and RebH 4-V which accept tricyclic tryptoline and large indole carbazoles.127
Scheme 5 Halogenation in the biosynthesis of the phenolic napyradiomycin 76 and merochlorins 77, 78: these natural products are synthesised from
polyketide derived tetrahydroxynaphthalene (THN), the biosynthesis of these suites of metabolites involve versatile VHPOs and employ a chemical logic
of chloronium formation promoting enantioselective intramolecular cyclisation.153,155 Chlorination is indicated in blue.
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respectively).133,134 Evidence points to a similar halogenation
strategy also being utilised in the biosynthesis of the peptidic
cyanobacterial products aeruginosin (AerJ), cyanopeptolin
(McnD), and cryptophycin A (CrpH) 60 of mixed PKS NRPS
origin.135,140 A similar biosynthetic logic is also predicted for the
glycopeptide antibiotics (GPAs). Vancomycin 62 (VhaA) and teico-
planin 61 (Tcp21), are two potent GPAs; again, these compounds
contain chlorinated tyrosine residues. In the case of the GPA
teicoplanin 61, careful in vitro investigations have shown that
Tcp21 accepts the peptidyl carrier protein (PCP) supported
aminoacyl substrate (tethered tyrosine), but will not accept the
dipeptide or extended peptides as substrate.136 In teicoplanin
biosynthesis, this amino acid residue is likely to be ß hydroxylated
at a later stage by a non-heme iron oxygenase, whilst in balhimy-
cin biosynthesis OH-Tyr, and not tyrosine, is incorporated by the
NRPS machinery.141 Analogues of tyrosine may also be accepted
by halogenases. SgcC3 accepts ß-tyrosine, probably also in carrier
protein tethered form, in the biosynthesis of the enediyne C-1027
64.137 In a similar manner, enzyme tethered 3-hydroxy-4-methoxy-
L-phenylalanine is seen to be processed to 2-chloro-3-hydroxy-4-
methoxy-L-phenylalanine by Pep1 in the first steps of the
biosynthesis of pepticinnamin G.142 In chondrochloren 65, 66
biosynthesis, CndH is indicated to process a different, perhaps
decarboxylated yet enzyme tethered analogue of tyrosine.36
Fig. 6 Representative bioactive natural products containing halophenol motifs, where the halogen is installed by a variant B FDH. Clorobiocin 58,133
simocyclinone D8 59,134 cryptophycin A 60,135 are all postulated to be generated from the halogenation of an enzyme tethered tyrosine residue, in the
first step (halogen added ortho in EAS fashion as mediated by Clo-hal, SimX1 and CrpH respectively). In vitro evidence supporting the early stage
halogenation of an enzyme tethered tyrosine exists for teicoplanin 61 and vancomycin 62 (mediated by Tcp21136 and VhaA).136 C-1027 64137 and the
chondroclorens 65, 66 are both postulated to arise from the halogenation of an enzyme tethered analogue of tyrosine, in the first stages of the
biosynthesis,36,138 whereas a first step of chlorothricin 63 assembly is thought to be the halogenation of enzyme tethered salicylate (catalysed by
ChlB4).139 Chlorination is indicated in blue. Different regio-chemistries for chlorination are represented by different shades of blue.
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Whilst many of the halogenases identified so far are seen to
accept electron-rich aromatic amino acids in the biosynthesis of
chlorothricin 63, ChlB4 is postulated to act on the small poly-
ketide subunit, 6-methyl salicylic acid139 (Fig. 6).
2.2.2 Late stage halogenation by variant A FDHs. Whilst the
variant B FDHs are not easily amenable to in vitro investiga-
tions, and are indicated to have a very limited substrate scope,
the variant A FDHs are less limited by these problems and offer
great opportunity for harnessing as biocatalysts. Amongst the
most exciting of these, are enzymes that are reported to act at a
late stage of the biosynthesis of structurally complex and
sterically bulky phenolic/quinolic natural products. Rdc2143
and RadH144 share 87% sequence similarity; these two enzymes
are identified to act in the final steps of biosynthesis of the
fungal polyketide natural product radicicol 67, an Hsp90 inhi-
bitor, within the fungi Pochonia chlamydosporia and Floropilus
chiversii respectively. GsfI operates in the final stages of the
assembly of griseofulvin 68, a clinically utilised antifungal
agent (Fig. 7).145 TiaM from tiacumicin B biosynthesis operates
in the final step of the biosynthetic pathway, functionalising a
complex and glycosylated polyketide generating both the mono
and dihalogenated products.226
CazI, from chaetoviridin A 68 biosynthesis, is postulated to
operate on a complex phenolic intermediate, in the final stages
of this cytotoxic polyketide.146 In a similar manner, CtcP is seen
to halogenate an advanced type II, aromatic polyketides core, in
the biosynthesis of chlortetracycline 73.147 Heterologous path-
way reconstruction studies indicate that in geodin biosynthesis
GedL dichlorinates the advanced PKS metabolite sulochrin,
directly affording dihydrogeodin 72.148 Aspirochlorine 70 is
an epidithiodiketepiperazine (ETP) toxin, produced by Asper-
gullus orizae, a mold used for millennia in Asian cuisine. The
first stages of the biosynthesis of aspirochlorine involve the
incorporation of two phenylalanines into a symmetric diketo-
piperazine (DKP). Intriguingly, one phenylalanine undergoes a
C–C cleavage to convert it into glycine. The other phenylalanine
is hydroxylated. AclH, operates in the final step of the biosynth-
esis, chlorinating the hydroxylated phenylalanine residue and
affording the toxin.149 XanH, a bifunctional FDH fused to its
concomitant flavin reductase, has been shown capable of
regioselectively chlorinating a complex late stage xanthone
intermediate on the path to xantholipin 74.150 Pentachlorop-
seudilin 71 has a series of interesting biological activities
including inhibiting TGF-beta signalling, and impairing angio-
genesis; yet its exact biosynthesis remains unclear. HalB was
found in a cosmid library of the producing organism; the first
halogenase identified from an actinomycetes. Notably, HalB
shows 55% sequence identity to the pyrrole FDH PrnC. HalB
has been shown to be capable, in vitro, of installing a single
halogen into 2-(3,5-dibromophenyl pyrrole), but, whether or not
it acts iteratively to install all 5 halogens in both the phenol and
pyrrole ring in the natural system remains unclear.151
2.2.3 Late stage halogenation by haloperoxidases. Vanadium-
dependent haloperoxidases (V-HPOs) have been identified that
are involved in the biogenesis of halophenol containing natural
products. The napyradiomycins (including napradiomycin B1
76) are polyketide-terpenoid natural products identified in
marine streptomycetes, over 50 members of this suite of natural
Fig. 7 Halogenated natural products where installation of halogen on a structurally complex non-tethered freestanding phenol is performed selectively
by a halogenase: including radicicol 67,143 griseofulvin 68,145 chaetoviridin A 69,146 aspirochlorine 70,149 pentachloropseudilin 71151 dihydrogeodin 72,148
chlortetracycline 73147 and xantholipin 74.150 Chlorination is indicated in blue.
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products have been identified so far. V-HPOs identified within
the biosynthetic gene cluster include NapH1, and NapH4.
NapH1 is particularly notable, this versatile enzyme acts upon
geranylated tetrahydroxynapthalene (THN) derivative, stereose-
lectively hydroxylating it whilst mediating regioselective
chlorination (Scheme 5). NapT8 and NapH3 operate succes-
sively to catalyse prenylation and then an a-hydroxy ketone
rearrangement. NapH1 then operates once more to halogenate
the newly introduced prenyl unit. The reaction is most likely to
proceed via a halonium species, which is then opened by the
hydroxyl that NapH1 previously introduced, thereby enabling
enantioselective cyclisation. In a similar manner, NapH4
mediates halogenation of the geranyl unit, again most likely
proceeding via the halonium species, and promoting intra-
molecular cyclisation.152 The complex cyclic scaffolds of the
merochlorins 77, 78 are formed using similar chemical logic.
Enzymatic total syntheses of napyradiomycin B1 76 has been
enabled in 18% yield.153
2.2.4 Substrate scope: phenols. Smaller, freestanding, non-
native phenolic substrates have been demonstrated to be
processed by variant A FDHs and HPOs (Fig. 8), revealing these
enzymes to be useful biocatalysts. The employment of the
HPOs, in this context, whilst enabling halogenation of sterically
bulky substrates, results in mixtures of regioisomers and poly-
halogenated compounds. This is a direct result of most HPOs
releasing free hypohalous acid; in this context, the enzyme has
little control over the regiochemistry of the transformation, and
it is simply the most electron-rich region(s) of the substrate that
are halogenated. In contrast, the FDHs usually accept much
smaller substrates but are generally highly regioselective. PltM has
been shown capable of mono 117 or di-halogenation 118
of phloroglucinol (Fig. 8J), as well as being able to accept resveratrol
as a substrate.51 Wild type RebH, GsfI, and ThaI have been shown
capable of processing a broad range of non-natural substrates
containing phenolic moieties.154 Exceptions may be seen with
RadH/Rdc2 and VirX1, FDHs with much more open and accessible
active sites, capable of regioselectively monohalogenating much
larger phenolic substrates.47,143,144
2.3 Pyrrolic substrates. Substituted pyrroles are also widely
used in medicine and agrochemistry. In nature, halogenases
may be found that are capable of mono- or poly-halogenating
pyrroles. Halopyrrole containing natural products include
pyrrolnitrin 24,34 pentachloropseudilin 71,151 chlorizidine A
131,162 hormaomycin 132,163 pyoluteorin 133164 and pyrrolo-
mycins 134–137165 (Scheme 6). PrnC, a variant A FDH,
chlorinates the pyrrole of 128 in the final step of pyrrolnitrin 24
biosynthesis.34 Here, the pyrrole is generated through the
cleavage and rearrangement of 7-chlorotryptophan 127
(Scheme 6). HalB, which shares 45% sequence identity with
PrnC, is implicated in halogenating the pyrrole of pentachloro-
pseudalin 71.151 For chlorizidine a 131, hormaomycin 132,
marinopyrrole 138,166 the pyrrole is formed by oxidation of a
proline uploaded onto an acyl carrier protein (ACP), the ACP
tethered pyrrole is then halogenated. Bmp2 is one such variant
B flavin-dependent pyrrole halogenase, mediating the
intriguing tetrabromination of the PCP-bound pyrrole ring,
with the introduction of the fourth bromide, to C1, apparently
triggering thioesterase mediated release and decarboxylation to
restore aromaticity.48 Curiously, the biosynthetically-related
halogenase, Bmp5, employs a chemically similar strategy of
decarboxylative bromination in the conversion of p-hydroxy-
benzoic acid to 2,4-dibromophenol (see Section 1.1.2). Mpy16
from marinopyrrole 138 biosynthesis is structurally similar to
Bmp2, yet stops at dihalogenation,166 as do Clz5162 and PltA164
in chlorazidine A 131 and pyoluteorin 133 biosynthesis, respec-
tively. Pyr29 is also postulated to di-halogenate an ACP tethered
pyrrole 130 in the biosynthesis of the pyrrolomycins,165 whilst
HrmQ from hormaomycin 132 biosynthesis mediates
monohalogenation.163 Structure-guided mutagenesis has been
performed on wild-type Bmp2 to generate a Bmp2 triple mutant
(Bmp2-TM) which proceeds no further than dibromination.48
2.4 Aromatic substrate scope beyond indole, phenol and
pyrrole. Though the vast majority of natural substrates for the
FDHs and haloperoxidases studied so far are indolic, phenolic
or pyrrolic in nature, they have been effectively employed in
installing halogens into other substrate classes. Generally, once
again, the FDHs are seen to confer greater regio- and substrate
specificity than the HPOs that generate and release free HOX.
Initial reports of wild-type flavin-dependent halogenases had
been indicative of a fairly modest and narrow substrate scope.
However, RebH, PrnA, PyrH, and SttH have been shown capable
of processing a series of anilines including kyuneride 171,
anthranilamide to give 172 and, to a lesser extent, anthranilic
acid to give 174 (Fig. 9C–F).79,80 These studies also gave insight
into factors governing regiospecificity. With PyrH, regiospecific
para-chlorination 171 of kynurenine was observed whereas
PrnA mediated the formation of the ortho-chlorinated product
166 exclusively, a product that is more chemically challenging
to access. PyrH could also be used to achieve the regiospecific
para-chlorination 172 of anthranilamide, whereas use of PrnA
resulted in a 86% : 14% para : ortho mixture. Mutations could be
effectively employed to modulate ortho:para selectivities and
improve yields for these unnatural substrates.79 Chlorination of
naphthalen-2-amine to give 165 by RebH ortho to –NH2 is
achieved in a high yield of 93%.126
The halogenation of sterically bulky substrates can be
enabled using haloperoxidases. As there is generally no sub-
strate binding site, and free HOX is released, the substrates that
can be halogenated using these systems are not limited by size.
However, as is usually expected for an HPO that releases HOX,
series of regioisomers, as well as mono, di, and tri halogenated
compounds result (Fig. 9G).169 For example, heme iron-
dependent chloroperoxidase (CPO) from C. fumago has been
used to give chlorinated analogues of naphthalene 182,
anthracene 183 and pyrenes 185 and 186. A vanadium-
dependent bromoperoxidase from the marine algae Ascophyl-
lum nodosum has also been employed mono and dibromination
4,6,8-trimethylazulene 179 (Fig. 9G), though the instability of
the resultant product hindered purification.168
To achieve regioselective electrophilic halogenation, generally
FDHs are needed, however, historically these have shown fairly
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Fig. 8 Representation of some of the diverse phenols that are accepted as non-natural substrates by different wild-type halogenases. All experiments
are in vitro, unless specified otherwise, and % conversions reported as determined by LC/LC-MS. Enzymes include (A) chloroperoxidase (heme iron-
dependent),156–158 (B) bromoperoxidase (vanadium-dependent)159 (C and D) AmVHPO (vanadium-dependent)107 (E) RadH (FDH) chlorination;144 (F) Rdc2
(FDH) chlorination and bromination;143,160 (G) RebH (FDH) chlorination126 (H and I) Bmp5 brominase (FDH) in vivo.45 (J) PltM (FDH) associated with
transcriptional regulation of pyoluteorin 43 biosynthesis,51,161 (K) VirX1 (FDH from a virus, the first FDH with a preference for iodination).47 Chlorination,
bromination and iodination are colour coded blue, red and purple respectively.
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narrow substrate scope. In 2019, new FDHs were revealed that
had been found using in silico genome mining approaches
(Fig. 9A and B). These halogenases were able to accept much
larger substrates and showed a much broader substrate scope
than any FDHs examined previously. VirX1, with a preference for
iodination, was demonstrated to be capable of regiospecifically
iodinating or brominating a diverse portfolio of substrates with a
variety of steric and electronic demands, and some of
which might be considered to be only weakly activated. Good
conversions of a wide range of unnatural substrates are possible
with this unusual enzyme from a virus.47 Similar infomatics-led
approaches have been utilised by the Sewald and Lewis groups,
further demonstrating that natural FDHs do exist with broader
substrate scope.170
2.5 Aliphatic substrate scope for biocatalytic halogenation.
The NHFeHals functionalise unactivated sp3 carbons. The
selective C–H activation that these enzymes are capable of is
challenging to achieve using even modern synthetic methodologies.
Prior to 1998, these radical halogenases were unknown, however,
the observation that the cyanobacterial natural product, barbamide
189, contained a leucine residue with one trihalogenated methyl
group, led Willis and co-authors to postulate that the enzymes
involved in its biosynthesis perhaps proceeded via a radical
mechanism.173 Over half a decade later, SyrB2, from the bio-
synthesis of syringomycin E 18246 by Pseudomonas syringae
B301D, was the first member of this new family of halogenases
to be biochemically and structurally characterised (Scheme 7).
Like the FDHs, the NHFeHals may be subdivided into those
that operate only on protein tethered substrates (which we call
here the variant B NHFeHals, to be consistent with the variant B
FDHs that also operate only on protein tethered substrates),
and the perhaps more biotechnologically useful, and recently
Scheme 6 Naturally occurring halopyrrole containing compounds. (A) The biogenesis of pyrrolnitrin 24 involving a variant A FDH PrnC. (B) The enzyme
tethered biosynthesis of halopyroles from proline, employing variant B FDHs. (C) Bioactive compounds containing halopyrroles including pyrrolnitrin
24,34 pentachloropseudilin 71,151 chlorizidine A 131,162 hormaomycin 132,163 pyoluteorin 133,164 pyrrolomycins 134–137165 and marinopyrrole 138,166
noting the halogenases utilised in their construction. (D) Biocatalytically vanadium-dependent bromoperoxidases may be utilised to monobrominate
thiophene and pyrroles.167 Chlorination is colour coded blue.

























































































This journal is © The Royal Society of Chemistry 2021 Chem. Soc. Rev.
discovered variant A NHFeHals that process free substrates
(see Section 1.2). The variant B type NHFeHals have proved
challenging to handle requiring anaerobic conditions, never-
theless they catalyse series of intriguing chemistries, including
cryptic halogenation en route to the installation of cyclopropyl
or alkynyl motifs, notable examples may be seen in jamaica-
mide 204,61 curacin A 208,174 coronatine 213175 and kutzneride
29 biosynthesis (Scheme 8).118 The need for covalent substrate
tethering prior to halogenation means that variant B
halogenases have less biotechnological potential at the current
time, and will be discussed just briefly in the following section.
2.5.1 Tethered substrates with unactivated sp3 carbon centres.
NHFeHals capable of processing a variety of very different
tethered substrates are known and have been shown to be
capable of selectively functionalising terminal methyl groups
and internal methylenes. Tri-chlorination of the pro-R methyl
of peptidyl carrier protein (BarA) tethered leucine 187 by
Fig. 9 Representative selection of aromatic moieties (beyond indole, pyrrole and phenol) that may be accepted as substrates for enzymatic
halogenation. Regiochemistry and conversions are given where reported in the primary literature. Enzymes include (A) genome mined VirX1, a variant
A FDH with a very broad substrate scope, the first halogenase to be isolated from a virus and the first FDH to show preference for iodination.47 Notably,
the regioselective halogenation of a diverse range of both small and large substrates may be seen including several less electron-rich and less activated
substrates (bromination of all substrates also possible). (B) A series of genome mined FDHs, again, halogenation of sterically more bulky substrates may be
seen (bromination of all substrates also possible).154 (C–F) Anilines and anthranilates processed by variant A FDHs RebH, PrnA, PyrH and SttH,
respectively.79,80,126 (G) Vanadium-dependent bromoperoxidase capable of brominating bulky substrates.168 (H) Heme-iron dependent chloroperox-
idases shown to be capable of processing bulky, planar modestly activated compounds such as pyrenes, mixtures of regiochemistries and levels of
substitution are observed.169 Chlorination, bromination and iodination are colour coded blue, red and purple respectively.
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tandem action of BarB1 and BarB2,60 and di-chlorination and
mono-chlorination of the g-methyl of peptidyl carrier protein
tethered L-2-aminobutyric acid 193 and L-threonine 190 by
CytC3 and SyrB2 has been demonstrated through in vitro
reconstitution experiments by Walsh and co-workers
(Scheme 7).58,171 CytC3 and SyrB2, have a level of similarity
(58% identity, 71%) similarity and process these subtly differ-
ent substrates. Beyond amino acids, NHFeHals are known that
can process tethered piperazines, fatty acids and tethered
polyketide intermediates. Examples include, KthP, which med-
iates the generation of the 5-chloropiperazyl motif in kutzner-
ide 29 biosynthesis,118 and HctB responsible for chlorination at
C5, of an acyl-carrier protein tethered hexanoate 199, in the
biosynthesis of the antifungal hectochlorin by cyanobacterium
Lyngbya majuscula (Scheme 7).172
2.5.2 Unactivated sp3 carbon centres, processed as free, non-
tethered substrates: enzymatic generation of alkyl halides. The
discovery of WelO5 from Hapalosiphon welwitschii UTEX B1830,
the welwintindolinone A 219 producer, by Liu and coworkers was
ground-breaking; for the first time, a NHFeHal could be seen to
process non-enzyme tethered substrates. Its regioselective and
stereoselective halogenation of a complex carbocycle, renders it
an exciting tool for biotechnological applications. WelO5 mono-
chlorinates 12-epi-fischerindole U 217 and 12-epi-hapalindole C
220 (Scheme 12),62 and has been demonstrated to enable
bromination of the same substrates, leading to their enhanced
antibacterial activity.176 Sharing 79% sequence identity with
WelO5, AmbO5 was subsequently discovered through the
analysis of the ambiguine 53 biosynthetic gene cluster.83,177
AmbO5 accepts a wider scope of substrates than WelO5 and
Scheme 7 Bioactive compounds where installation of halogen on a protein-tethered aliphatic substrate is performed selectively by a NHFeHal,
including (A) barbamide 189,60 (B) syringomycin E 192,58 (C) armentomycin 196,171 (D) kutzneride 2 29118 and (E) hectochlorin 200.172
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selectively chlorinates a range of fischerindole (52, 53), hapalin-
dole (222) and ambiguine alkaloids (56) (Scheme 9A).83 By
generating hybrid enzymes consisting of the N-terminus of
WelO5 and C-terminus of AmbO5 (and vice-versa), some success
of halogenating a slightly wider scope of hapalindole type
molecules was achieved.83
Initial sequence and mutational analysis of WelO5 and
AmbO5 pointed to eleven C-terminal residues, likely influencing
substrate utilisation.180 The potential to develop WelO5 through
directed evolution to improve the biocatalytic capabilities and
extend substrate scope has been attempted by a number of
groups. Hoebenreich and coworkers used structure-guided
direct evolution to develop variants of WelO5 homologue
Wi-WelO15 from Westiella intricata HT-29-1 capable of selectively
chlorinating non-natural hapalindole 235, and hapalindoles
237–240 containing a ketone moiety at the position of the
natural isonitrile.178 Buller and coworkers engineered variants
of another homologue WelO5* for selective halogenation at two
separate positions on a martinelline analogue 232,179 representing
the first successful biocatalytic installation of a halogen by WelO5
type enzymes on a substrate that is notably different to their natural
hapalindole targets. Both Buller and Hoebenreich identified amino
acid positions, which seem to play an important role in the
regioselectivity of these enzymes towards non-natural substrates,
opening up possible opportunities for rational re-engineering of
these catalysts.
The co-crystal structure of WelO5 and native substrate was
used in a structural search for other enzymes capable of alkyl
halogenation of different substrates. In this manner, the hydro-
xylase SadA was identified. Minor modification to the active site
and coordination of the FeII (D157GSadA) resulted in an
enzyme capable of chlorinating as well as hydroxylating its
natural substrate.182
A second series of variant A NHFHals that operate
on substrates that are not covalently tethered to a carrier
protein (free substrate NHFe halogenases) have recently been
Scheme 8 Installation of halogen on protein-tethered aliphatic substrate performed selectively by a NHFeHals, in the biosynthesis of natural products,
enabling alkene generation and cyclopropane generation. (A) Jamaicamide 204,61 (B) curacin A 208,174 (C) coronatine 213,175 and (D) kutzneride 29.118
Notable similarities may be observed between the first steps in jamaicamide, vinylchloride formation and curacin cyclopropyl biosynthesis. Coronamic
acid and kutzneride 29 biosynthesis are initiated by the halogenation of the g-methyl of different diastereoisomers of L-isoleucine.
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discovered, and named the BesD family. Like CurA, CmaB,
KtzD (Scheme 8) and JamE, BesD is a cryptic halogenase, and
was discovered in the biosynthetic pathway of the amino acid b-
ethynylserine 247 (bes) from S. cattleya, after knockouts of non-
essential amino acid desaturases pointing towards a novel
enzymatic production of the alkyne moiety.183 Purified BesD
was shown to selectively chlorinate free lysine 245, producing
4-Cl lysine 246.84 Subsequent C–C cleavage and elimination of
the installed chlorine was shown to lead to the terminal alkyne
(Scheme 10A). BesD has low sequence identity to both substrate
bound SyrB2 (7%) and variant B prototype WelO5 (11%),
instead having a much higher identity to predicted hydroxy-
lases (446%). Rather than being a standalone enzyme, BesD
was shown to be part of a variant A NHFeHals.84 Homology
networks were produced from hits arising from a sequence-
based homology search of BesD. This approach resulted in the
discovery of 20 more halogenases that act on free amino acid
substrates. The range of substrates was diverse, with BesD and
other enzymes accepting lysine but also ornithine, while the
hydrophobic amino acids leucine, isoleucine, and norleucine,
Scheme 9 Known substrate scope of wild-type NHFeHals WelO562 and AmbO583 and engineered varieties of WelO15178 and WelO5*.179
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were shown to be substrates for PrHalE (Scheme 10A).
A selection of these halogenases was shown to perform along-
side amino acid metabolising enzymes to produce chlorinated
heterocycles, diamines, and a-keto acids from lysine (SwHalB),
ornithine (PkHalD), and norleucine (PrHalE). Remarkably, all
enzymes retained fidelity for halogenation over hydroxylation,
while the radical halogenase HalB (different to the FDH HalB)
from Streptomyces wuyuanensis (SwHalB) was able to accept
bromine and azide anions to produce bromo-lysine and
azido-lysine. Chlorolysine, generated by SwHalB and PfHalA,
could also be incorporated into a 9 amino acid peptide using an
in vitro transcription and translation system-suggesting a
potential use for these enzymes in production of more complex
natural product analogues.84
Recently, variant A NHFHal capable of halogenating nucleo-
sides, named AdeV, has been discovered in the biosynthesis of
Scheme 10 NHFe halogenases. (A) Known substrate scope of the NHFe halogense BesD and enzymes from the BesD family,84 (B) AdeV chlorination of
20-dAMP in adechlorin biosynthesis and other known substrates of AdeV,85 (C) SaDAH chlorination in acutumine biosynthesis.181
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the chlorinated natural product adechlorin 260 in Actinomadura
sp. ATCC 39365, opening up the path to access valuable
halonucleosides85 (Scheme 10B). AdeV was shown to have
15% similarity to WelO5. Gene knockout experiments confirmed
its role in adechlorin biosynthesis. AdeV acts in the early stages
of biosynthesis on free nucleoside 20-deoxyadenosine-50-
monophosphate (20-dAMP) 258 to generate 20-Cl-20-dAMP.
In vitro assays revealed that 20-deoxyadenosine (20-dA), identical
to 20-dAMP apart from the 50- phosphate moiety, was not accepted
as a substrate, indicating that the presence of this phosphate is
essential for substrate binding and halogenation activity.
Consistent with this logic, two other phosphorylated nucleosides
20,30-dideoxyadenosine monophosphate 261 and 20deoxyinosine-
50-monophosphate (20-dIMP) 263, were accepted by AdeV and
converted to their chlorinated counterparts indicating a level of
enzyme promiscuity. However, the natural substrate 20-dAMP
showed the highest levels of conversion.
Several plant species are known to generate halogenated
metabolites. The toxin fluoroacetate is produced in many plants
including Camellia sinensis (from which tea is generated). Fatty
acid derivatives of fluoroacetate such as o-fluorooleic acid
accumulating in the seeds of Dichapetalum toxicarium.181 An
exciting new NHFe halogenase DAH that performs the stereo-
selective late stage chlorination of the complex alkaloid dechlor-
oacutimine 265, (Scheme 10C) produced by menispermaceae
plants, has been found and its activity demonstrated in vitro.
This represents the very first NHFeHal found in plants.181
Phylogenetic analysis indicates that DAH, which has a variant
in Menispermaceae canadense (McDAH) and Sinomenium acutum
(SaDAH), evolved independently from the previously discussed
bacterial NHFeHAls, potentially being an example of parallel
evolution in halogenated natural product metabolism. In vitro assays
against a wide range of alkaloids indicated that DAH was highly
selective towards its natural substrate, with no other small molecules
being accepted for halogenation. As with some other halogenases,
DAH was shown to accept azide anions as well as halides, and
convert ()-dechloroacutumine to 11-azido-dechloroacutumine.
Beyond the NHFe halogenases, alkyl halides can be generated
by a series of vanadium-dependent haloperoxidases. An elegant
cyclisation cascade is initiated by the selective bromination of a
single alkene within a terpenoid; the resultant bromonium
undergoes ring opening affording the alkyl bromide. For example,
the vanadium bromoperoxidase from C. officinalis brominates
the terpenoid precursor (E)-(+)nerolidol 267, yielding cyclised
snyderols 268-230.184 For b- and g-snyderol, a single diastereo-
isomer is produced. This provides an exciting biocatalytic oppor-
tunity as synthetic methods have succeeded only in forming a
mixture of two diastereoisomers of each product (Scheme 11). In a
similar manner, chlorination, mediated by haloperoxidases, may
be seen to generate chloronium species, initiating cyclisation
cascades. Installation of chlorine onto the aliphatic moiety of
SF2415B1 by NapH1 allows cyclisation of the structure to afford a
cyclic ether, offering potential for synthesis of napyradiomycins 76
(Scheme 5) with cytotoxic and antibacterial properties.155
Notably, a small number of FDHs process aliphatic compounds.
One such example is CmlS, an FDH from chloramphenicol
biosynthesis implicated, through in vivo studies, in the generation
of a dichloroacetyl moiety.185 In this unusual FDH, the flavin
cofactor is covalently linked to the enzyme. The malonyl-CoA
substrate is proposed to form an enolate, stabilised through
hydrogen bonding to tyrosine, this species may then react with a
proximal chloramine.44 Beyond the halogenation of tethered
malonyl-CoA by CmlS, other exciting observations of the applica-
tions of these enzymes are noted. Intriguingly, an FDH from a
fungus, AoiQ, has been demonstrated to regioselectively chlorinate
an unactivated terminal sp3 carbon of a freestanding molecule 271,
in the biosynthesis of orthosporin (Scheme 12). So far, AoiQ is
unique amongst other flavin-dependent halogenases in its ability to
perform this task. Although the mechanism for this reaction is
unknown, it has been postulated by Hertweck and coworkers that,
though it is a FDH, it may proceed via a radical reaction.186 Notably,
like KrmI, it is one of the few fused halogenases to be explored.
In the case of AoiQ, it contains a functional O-methylation domain.
The mystery as to how it operates remains to be revealed.
3. Approaches toward improved biocatalytic halogenation,
and steps toward upscaling
Considerable effort has been invested into engineering and
evolving the biocatalytic activity of halogenases. Studies have
predominantly focussed upon the FDHs in order to alter
substrate profiles, modify regiochemistries of halogenation
and enhance biocatalytic stability. Greater structural under-
standing of these enzymes has enabled progress to be made
in their rational redesign.187,188 Such approaches combined
Scheme 11 V-BrHPO catalysed terpene bromination and cyclisation
event in snyderol biosynthesis.184
Scheme 12 FDH AoiQ dichlorination and dimethylation of diaporthin
271.186
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with substrate walking methods189 have enabled the utilisation
of halogenases in the selective decoration of increasingly more
complex substrates, as well as stabilising enzymes to operate at
higher temperatures.190 Engineering of the NHFeHals has also
enabled their application to a broader series of substrates
(see Section 2.2.4).178,179 Though the evolution of a small number
of tryptophan halogenases for utilisation for halogenation of a
broader series of substrates has proved useful, other approaches
have considered the natural diversity of the halogenases. The
broad range of halogenated structures that have been noted, over
5000 to date,13 together with the variety of organisms from which
they are produced, indicates that many diverse halogenases
remain to be discovered. In silico discovery approaches have been
utilised to mine for various halogenases within uncurated
genomic deposits, leading to the discovery of more substrate
flexible halogenases from diverse sources including viruses.47,170
Discovery of novel halogenases remains at the forefront of
biocatalytic halogenation research. For effective biocatalysis, good
amounts of soluble protein are required. The Lewis group have
effectively improved heterologous production of RebF through
including a cleavable maltose binding protein (MBP) tag, to
enhance solubility of the enzyme, and co-expressing both the
halogenase and the concomitant reductase, RebF with the
chaperonins GroEL/ES, in addition to developing a cofactor
recycling system.126 Advances on FADH2 regeneration have
recently been achieved by replacing NADH with synthetic
mimics.191 A photocatalytic approach has been successfully
applied to the VHPOs. The Gulder group cleverly demonstrated
that by illuminating their biocatalytic system with 455 nm light,
and including sacrificial electron donors, cofactor recycling could
be addressed, and a ready supply of reduced cofactor afforded in a
relatively inexpensive manner.192,193 An approach that has made a
significant difference to the utilisation of FDHs is the application
of cross-linked enzyme aggregates (CLEA). FDHs generally have
poor stability, impacting their catalytic longevity and utility in
scaled up reactions. The robust nature and solvent tolerance of
Cross-Linked Enzyme Crystals was first reported in the early
1990s, but the technique required the enzymes of interest to first
be crystalised.194 The application of CLEA was first demonstrated
for PenAcylase, an aminoacylase utilised in the generation of
ampicillin, where CLEA were generated from precipitating, rather
than crystallising, the enzyme prior to cross-linking.195 By using a
CombiCLEAS approach of 1 g of L-tryptophan to 1.8 g of L-7-Br-
tryptophan could be achieved with complete conversion within an
8 days period.130 To achieve this, the lysate from Escherichia coli
(E. coli) (6 L), that had been grown with a RebH expression vector,
was combined with PrnF, the flavin reductase from Pseudomonas
fluorescens, and an alcohol dehydrogenase from Rhodococcus sp.,
that had been precipitated with ammonium sulfate, was then cross-
linked with 0.5%/wt glutaraldehyde to form the CombiCLEAS.
4. Site selective C–H activation through hyphenation of
enzymatic halogenation and synthetic diversification
The opportunity to combine enzymatic halogenation with
chemical modification, in particular catalytic cross-coupling,
is exciting and provides a much-needed tool for molecule
constructions. This concept, first reported in 2010, with the
tryptophan halogenase PrnA being utilised to give access to a
new to nature haloindolic natural product, which was
subsequently functionalised through Suzuki–Miyaura cross-
coupling,196 has been gaining momentum. This section
comprehensively reviews the current state-of-the-art and
reflects on technologies enabling the hyphenation.
4.1 Aqueous compatible cross-coupling methodologies.
Palladium-catalysed cross-coupling reactions play a central role
in organic chemistry. Their utility in the formation of C–C and
carbon–heteroatom bonds under mild conditions with a wide
range of organic halide and nucleophilic reagents, has led to
them being one of the most utilised series of reactions in the
pharmaceutical industry.197 As with almost all enzymes, the
halogenases require an aqueous environment for effective
operation. To effectively couple enzymatic halogenation with
synthetic diversification, aqueous compatible reaction conditions
are generally required. Palladium-catalysed cross-coupling
reactions have largely utilized traditional organic solvents.
Standard conditions for these coupling methodologies typically
use a mixed organic/aqueous base solvent system, hence the
development of water solubilising ligands have been highly
enabling. The first example of a water-soluble palladium catalyst
for cross-coupling reactions being reported by Casalnuovo,198 and
significant effort has been devoted to the development of hydro-
philic palladium/ligand complexes for aqueous-phase catalysis
since this seminal work, as well as active hydrophobic catalysts
and ligand-free species based on palladium nanoparticles.199–203
The development of mild cross coupling conditions for the
modulation of challenging and or functionally sensitive com-
pounds is advancing, enabling the diversification and tuning of
small molecules, natural products and biomolecules including
nucleic acids and peptides. To this end, aqueous compatible and
water soluble ligands such as TPPTS 274,199 and the sterically
demanding and electron-rich TXPTS 275,199 sSPhos 276,204
SXPhos 277204 and disodium 2-aminopyrimidine-4,6-diol
278205–207 have proved valuable (Fig. 10). Additionally, nitrogen
based ligands enabling aqueous compatible cross-couplings such
as tetramethylguanidine 279 and 2-(dimethylamino)-pyrimidine-
4,6-diol 280, both reported to have low cell toxicity, are beginning
Fig. 10 Selected water-soluble ligands used for aqueous Suzuki–Miyaura cross-
coupling reactions in the presence of halogenase enzymes or even living systems.
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to facilitate tandem halogenation and cross-coupling strategies in
living systems.208
Specifically, with the goal of enabling C–H activation
through enzymatic halogenation and chemical cross-coupling,
our team has developed series of aqueous cross-coupling
procedures, enabling the cross-coupling to be compatible with
molecules decorated with sensitive functional groups, as well as
with enzymes and even in live cell environments. We have
initiated our development of these catalytic conditions by
focussing on challenging free and unprotected halotrypto-
phans. Our choice has been directed by three factors:
– The availability of a well-characterised series of tryptophan
halogenases that may be utilised in standalone format in
conjunction with a biosynthetic pathway to access halotrypto-
phans and synchronously new-to-nature halotryptophan
containing natural products;
– The utility of tryptophan as a fluorescence tag and a moiety
that governs protein folding, and the attraction to being able to
tune these properties;
– And the challenge that free tryptophan confers, rendering
it a suitably stimulating test bed. We reasoned that by
developing conditions that were suitable to address the cross-
coupling of free halotryptophan, a small molecule with the
propensity to coordinate to the catalyst and render it inactive,
such conditions could be readily applied to other more
tractable moieties. To this end, we developed a range of
aqueous conditions enabling the Suzuki–Miyaura,209 Heck,210
Sonogashira,211 keto-arylation212 and Buchwald–Hartwig213
diversification of free unprotected tryptophan, peptides, and
natural products (Scheme 13).
The development of mild aqueous chemistries has facilitated
chemo-enzymatic and GenoChemetic approaches. Site selective
C–H activation is enabled by a halogenase and synthetic diversi-
fication carried out, in some cases synchronously, through
aqueous compatible Pd mediated catalysis. More reactive aryl
iodides and bromides can be coupled under much milder
conditions than their less activated chloro counterparts.
4.2 Chemo-enzymatic approaches. Hyphenation of enzymatic
halogenation and synthetic derivatisation has been enabled by
steering, where possible, to enzymatic bromination (or even iodina-
tion) over enzymatic chlorination, employing combinations of
stabilised or partitioned enzymes, and use of mild and aqueous
cross-coupling methodologies. There is burgeoning interest in
employing such strategies as powerful methods for late-stage
diversification on ever more complex molecules. The approach
is also utilised to enable a fast fluorescence assay for enzyme
screening and for directed evolution. A few enzymes, such as RadH
have been shown capable of halogenating 7-hydroxycoumarin.
An enhancement in fluorescence occurs when 7-hydroxycoumarin
(lmax 325 nm) is converted to 8-chloro-7-hydroxycoumarin
(lex 386 nm/lem 456 nm).
144 In most halogenation reactions, a
clear change in fluorescence is not always observable, and cross-
coupling chemistry has been employed to provide a fluorescence
readout that may be used to assay halogenase activity. Sewald
reported the utilisation of tryptophan 5-, 6- and 7-halogenases
PyrH, ThaI, and RebH for bromination of L-tryptophan
substrate.214,215 The team then employed aqueous cross-coupling
conditions. To achieve cross-coupling of the bromo-tryptophan
product within the crude lysate, the Pd-catalyst loading was further
increased to 50 mol%. By reaction with the boronic acid of aniline,
the products (30-aminophenyl)-tryptophans were reported to have a
lex 300 nm/lem 430 nm (Scheme 14B). This technology was utilised
for microtitre plate screening enabling rapid analysis of
ThaI mutants that had been generated by error-prone PCR.215
The Sewald team also cleverly employed CLEA technology (see
Section 3) to enable bromination of tryptophan by these same
halogenases PyrH, ThaI, and RebH. Not only did the utilisation of
enzyme aggregates afford stabilisation, but it also provided an
opportunity for readily filtering off the enzymes ahead of Suzuki–
Miyaura diversification of the resultant halotryptophans. By utilis-
ing a three-step approach, organic solvents required for solubilisa-
tion of several of the substrates could be used, with Boc protection
being carried out in a final step, thereby easing purification.214 In a
similar manner, the Sewald group developed a three-step one pot
reaction utilising RebH and Mizoroki–Heck chemistry for the
further diversification of tryptophans. Again, by using their
combi-CLEA system in a stepwise manner (Scheme 14D), the
harsher reaction conditions required for Heck diversification
could be utilised and enabled the generation of C-7 substituted
styryl-tryptophan with a lem of 485 nm (lex 360 nm), and Stokes
shift of 7159 cm1.216
This larger Stokes’ shift renders this technology potentially
very useful for molecule tagging and enzyme assay, as well as
valuable for molecule diversification. Even when stabilised as
CLEA, enzymes and Pd catalysts can have poor compatibility.
To achieve a synchronous one-pot enzymatic halogenation and
chemical cross-coupling, and to avoid the additional filtration
step, Micklefield and co-workers elegantly partitioned CLEA
stabilised PyrH, RebH, RadH and SttH from the Pd catalyst
through use of a polydimethylsiloxane (PDMS) membrane.
Whilst the brominated enzymatic product could pass through
the PMDS, it was reported to be impervious to the enzymes and
cofactors. The cross-coupled product, once formed, remained
in the chemo-catalytic chamber (Scheme 14G).218
Though the majority of chemo-enzymatic approaches
published so far have focussed on tryptophans and other
indolic systems, this is predominantly a reflection of the most
extensively studied FDHs. Through substrate walking method-
ology, Jared Lewis and co-workers have impressively evolved
RebH to work on substrates that are chemically distinct from
its natural tryptophan substrate. Utilisation of evolved halo-
genases enabled bromination of a diverse series of substrates
including tryptolines, sterically bulky substituted anilines as
well as carvediol and pindolol, two clinically utilised beta-
blockers. Conditions to enable Suzuki–Miyaura, Buchwald–
Hartwig amination and alkoxylation were developed and
applied mostly to the chlorinated and brominated intermediates
as a component of a crude extract, resulting in high yields of
the respective products 284–289 (Scheme 13D–F).189 With the
discovery of more substrate diverse halogenases, engineering of
known halogenases, enzyme stabilisation and partitioning
strategies and the development of milder reaction conditions,
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Scheme 13 Mild aqueous conditions enabling the cross-coupling of free unprotected halotryptophan and halotryptophans embedded into natural
products, biomolecules and bioactive compounds. Colour code: Blue background: conditions enable processing of aryl-chlorides in addition to more
reactive aryl-bromides, Red background: least activated aryl halide processed is Ar–Br under these conditions (broad substrate scope and extension of
chemistry to other systems not shown here). (A) Suzuki–Miyaura cross-coupling on bromotryptophans: phenylboronic acid (1.1 equiv.), Na2PdCl4
(2.5 mol%), TXPTS (25 mol%), K2CO3 (5 equiv.), water, 40–80 1C, 70–90% isolated yields.
209 (B) Suzuki–Miyaura cross-coupling on chlorotryptohans, and
7-chlorotryptophan pacidamycin: phenylboronic acid (1.5 equiv.), Na2PdCl4 (5 mol%), SPhos (10 mol%), K2CO3 (5 equiv.), water:acetonitrile 80 1C, on
purified material and crude extract 60–70% isolated yields.217 (C) Suzuki–Miyaura cross-coupling of bromotryptohans, p-tolylboronic acid (3 equiv.),
Pd(OAc)2-[2-amino-pyrimidine-4,6-diol]2 (5 mol%), K2CO3 (6 equiv.), 45 1C, 54–85% isolated yields and 7-bromotryptophan pacidamycin in living
cultures: reaction carried out in optimised culture medium at 37 1C.206 (D) Ketoarylation of N-Boc-bromotryptohans, and small water-soluble chloro and
bromo pharmacophores: ketone (4 equiv.), [Pd(DtBPF)Cl2] (DtBPF = 1,10-bis(di-tert-butylphosphino)ferrocene) (2 mol%), NaOH (4 equiv.), dioxane : water
1 : 1, 60 1C, 45–94% isolated yields.212 (E) Buchwald–Hartwig diversification of chloro and bromotryptophans, peptides containing bromotryptophan and
the bromotryptophan containing natural product barettin: aniline (2 equiv.), [Pd(tBu-XPhos)G1] (5 mol%), KOH (4 equiv.), dioxane : water 1 : 1, 100 1C,
8–48 min, 31–75% isolated yields.213 (F) Sonogashira diversification of bromotryptophans, peptides containing bromotryptophan and the new to nature
bromotryptophan containing natural product cystargamide: alkyne (1 equiv.), [PdCl2(CH3CN)2] (5 mol%), sXPhos (15 mol%), Cs2CO3 (2.5 equiv.),
acetonitrile : water 1 : 1, 100 1C, 25–97% isolated yields.211 (G) Heck diversification of bromotryptophans, peptides containing bromotryptophan
7-bromotryptophan containing pacidamycin: alkene (1.5 equiv.), Na2PdCl4 (10 mol%), TXPTS (23 mol%), Na2CO3 (4 equiv.), acetonitrile : water 1 : 3,
90 1C, 51–95% isolated yields.210
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the portfolio of functionalisable systems is set to expand
significantly.
FDHs are not the only halogenating enzymes to be merged
with palladium catalysed cross-coupling. V-HPOs and HPOs
Scheme 14 Hyphenation of halogenation and cross-coupling to achieve C–H activation, (A) general concept in which the halogenase operates first,
and then the cross-coupling is carried out on the halogenated material as a component of the crude extract. This is carried out stepwise in (B–F),
enabling access to a broad series of compounds, and synchronously in G where the halogenation and cross-coupling events are spatially separated
through application of a membrane. (B) Bromination of L-tryptophan by Thal, followed by Suzuki–Miyaura cross-coupling of the brominated product as a
component of the crude lysate.215 The product of cross-coupling (lex 300 nm/lem 430 nm) is used in screening the directed evolution of RebH, resulting
in a 2.5-fold increase in enzymatic activity. Cross-coupling conditions: 3-aminophenylboronic acid (10 equiv.), Na2PdCl4 (50 mol%),
SSphos (150 mol%),
K3PO4 (15 equiv.), 95 1C.
215 (C) One-pot bromination of L-tryptophan by RebH-CLEA, followed by Mizoroki–Heck cross-coupling, in a stepwise fashion to
afford C-7 substituted 7-(4-carboxystyryl)tryptophan with a lem of 485 nm (lex 360 nm). Cross-coupling conditions: 4-carboxystyrene (5 equiv.), PdOAc2
(0.1–0.2 equiv.), TPPTS (0.3–0.6 equiv.), K2CO3 (5 equiv.), water, degassed under argon, 100 1C.
189 (D–F) Sequential enzymatic bromination by evolved
RebH variants, followed by (D) Suzuki–Miyaura, (E) Buchwald–Hartwig, (F) alkoxylation of tryptophan as a component of a crude extract. Conditions D:
ArB(OH)2 (1.5 equiv.), PdOAc2 (0.05 equiv.),
SSPhos (0.05 equiv.), iPrOH: phosphate buffer (170 mM, pH 8.5) 1 : 1, 90 1C. (E) ArNH2 (3 equiv.), PdOAc2
(0.03 equiv.), BrettPhos (0.03 equiv.), NaOt-Bu (6 equiv.), dioxane, 100 1C. (F) CF3CH2OH (2 equiv.), [(allyl)PdCl]2(0.005 equiv.), RockPhos (0.015 equiv.),
Cs2CO3 (2 equiv.), toluene, 90 1C.
189 (G) One-pot, synchronous halogenation and Suzuki–Miyaura cross-coupling by PDMS membrane separated RebH-
CLEA and Pd catalyst. Cross-coupling conditions: PdOAc2 (10 mol%), 2-(dimethylamino)-pyrimidine-4,6-diol (20 mol%), aryl boronic acid (5 equiv.) and
CsF (10 equiv.), r.t. overnight then 80 1C.211
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Scheme 15 GenoChemetic approaches to C–H functionalisation of small metabolites and complex natural products. Here, a halogenase is installed to
complement an existing metabolic/biosynthetic pathway, the halogenated natural product is diversified through application of cross-coupling
chemistries. (A) Two step approach: hairy root cultures of Catharanthus roseus are engineered to include RebH, PyrH and their concomitant reductases.
A series of chlorinated and brominated analogues are produced, and cross coupling has been carried out on purified compounds and on the metabolites
as components of crude extracts, enabling access to a wide portfolio of functionalised molecules.224 Cross-coupling conditions: arylboronic acid
(3 equiv.), Pd(OAc)2 (5 mol%), Sphos (13 mol%), K3PO4, n-butanol, 100 1C, 10–60 min. (B and C) One pot approach, pathways constructed in heterologous
hosts, with halogenation (mediated by PrnA)225 and cross-coupling occurring synchronously in the presence of the living E. coli and Streptomyces
coelicolor,222 respectively.
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have been successfully used in various chemoenzymatic halo-
cyclization reactions,219,220 and recently this has been merged
with homogenous metal catalysis for further diversification.
Deska and coworkers enabled the one-pot combination of
allenol halocylization using CPO from Caldariomyces fumago
and glucose oxidase from Aspergillus niger (GOx) with SPhos
catalysed Suzuki–Miyaura and Sonogashira coupling to
diversify a range of dihydrofurans. Excitingly, a nanobiohybrid
was also generated using GOx as a support for palladium
nanoparticles, which led to good yields of stepwise halocycliza-
tion and Suzuki coupling.221
4.3 GenoChemetic approaches. Whilst in an enzymatic or
whole cell biotransformation where the enzymes or cells are
exogenously supplemented with substrates, in a GenoChemetic
approach, the substrate and tagged intermediates are fully
biosynthesised by an engineered organism. GenoChemetic
processes provide an expeditious route to generating series of
analogues of natural products. Semi-synthesis, though a useful
tool, is limited by the innate functional groups naturally
present within the molecule. GenoChemetics addresses this.
It involves the introduction of a gene to complement a biosyn-
thetic pathway, such that a chemically reactive and orthogonal
handle is introduced into the natural product. This handle
enables synthetic diversification of the natural product. There
are so far three reports of the utilisation of halogenases within
GenoChemetic systems. In each of these systems, tryptophan
halogenases have been employed, with RebH, PyrH, and PrnA
being installed into either pathway engineered or wild-type
strains enabling the production of chlorinated or brominated
analogues of the complex natural product scaffolds.
The halogenated metabolites have been subjected to cross-
coupling chemistries. In the first example, the tryptophan
halogenase PrnA was installed, through use of an integrative
vector, into the genome of Streptomyces coeruleorubidis. It was
demonstrated that there was no need to introduce PrnA’s
concomitant flavin reductase, as the organism’s own reductases
sufficed. A chlorinated analogue of pacidamycin, a uridyl peptide
antibiotic, was produces at a titre of B1 mg L1. In spite of
bearing series of sensitive functional groups, this metabolite
could be readily cross-coupled using the moderately mild
Suzuki-Miyaura conditions that were developed. The cross-
coupling was carried out both on the purified material and on
material as a component of a crude extract (Scheme 15). The
latter was preferable, as the more lipophilic product that resulted
was much more readily amenable to purification.217 The
generation of brominated analogues would, of course, facilitate
cross-coupling under even milder conditions. However, Strepto-
myces coeruleorubidis was found to be sensitive to bromide salts,
and the brominated analogue cannot readily be accessed
through use of this strain. Streptomyces coelicolor showed good
tolerance to bromide salts in a screen of series of potential
heterologous expression hosts, and so the pacidamycin
biosynthetic gene cluster, identified previously, was ported into
this strain conferring it with the ability to produce pacidamycins.
The gene encoding the halogenase PrnA was engineered into the
strain and ability to produce bromo-pacidamycin was confirmed.
In order to enable bromometabolite production and cross-
coupling synchronously, mild cross-coupling reactions that
enabled derivatisation of 7-Br-pacidamycin D 305 in the
presence of the living culture were carried out. In a similar
manner, E. coli was engineered with the ability to make bromo-
tryptophan and its cross-coupling to 306 affected in the living
fermentative culture.222 A similar system was designed in hairy
root cultures of Catharanthus roseus in which they were engi-
neered to include RebH, PyrH and their concomitant reductases.
This led to the production of a range of chlorinated and
brominated analogues of the plant’s monoterpene indole
alkaloid natural products 299–301, which were successfully
extracted and coupled in non-aqueous Suzuki–Miyaura couplings,
either as crude extracts or purified compounds (Scheme 15A).223,224
Conclusions
Though enzyme mediated halogenation was initially considered
to be nothing more than an artefact or a rare event, today over 30
enzymes capable of mediating such chemistry have been
structurally and biochemically characterised (Table 2), and an
even greater number subject to in vitro and in vivo investigation.
Halogenated compounds play a major role in the construction of
molecules via cross-coupling methodologies, as well as making
up a large percentage of medicinally and agrochemically relevant
molecules. In a world that seeks more selective, greener and
more sustainable solutions to molecule manufacture, halo-
genases hold an opportunity. They also offer potential for the
vectorisation of fragments for SAR. Whilst the kinetic analyses of
the halogenases is rather potted, drawing this data together is
useful in identifying potential halogenases for development and
use in biotransformations. Whilst the HPOs are capable of
mediating halogenation of large and sterically demanding sub-
strates, as most neither bind the substrate nor the electrophilic
species, such systems generally lack regiocontrol. A few
intriguing departures from this trend have been identified from
marine systems, indicating that there is much more to learn
about these enzymes, their operation and evolution. New variant
A FDHs with reasonable catalytic efficiency and broad substrate
scopes have been revealed in the last two years, enabling
regioselective chlorination, bromination and even iodination
on sterically and electronically demanding aromatic systems,
even prior to rational redesign or evolution. Excitingly, in recent
years the range of variant A NHFeHals that enable the controlled
halogenation, including stereoselective halogenation, have been
identified; clearly, there are many more such systems awaiting
discovery. Inspired by such systems, it may be possible to
generate artificial architectures that, perhaps via haloamines,
position and deliver electrophilic halogenating agents to
substrates held in the required position to affect desired
regiochemistries.
Halogenation introduces a chemically reactive, chemically
orthogonal moiety into a compound. This single atom
modification, that can be genetically/enzymatically installed
has the potential to act as a superior tag to azide or alkyne
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modifications. In parallel with halogenase discovery, a variety
of aqueous cross-coupling reactions compatible with sensitive
functionalities in natural products and biomolecules have been
developed. Some of these reactions are even biorthogonal.
The opportunities for building pathways and circuits of
SynBio-SynChem present themselves.
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